Wiwanikit has several concerns about our report on the effectiveness of treating the host response of patients with Ebola virus disease using a combination of a statin (atorvastatin) and an angiotensin receptor blocker (ARB) (irbesartan) (1, 26). First, not all of the endothelial damage in Ebola described by Baskerville et al. in 1985 was caused by thrombotic events. The ultrastructural changes “took the form of separation of junctions between endothelial cells and detachment from basement membranes. These focal lesions were associated with edema and hemorrhage. Diffuse endothelial injury and loss of endothelial integrity combined with the histochemical changes observed in the animals probably led to hypovolemic shock” (2). A decade later, Feldmann et al. showed that filovirus replication in human monocyte/macrophage cell cultures released inflammatory cytokines that caused an increase in endothelial permeability (3). Virus infection of endothelial cells alone was thought to be insufficient to cause this change (2, 3).

Second, Wiwanikit cites a study that showed higher plasma levels of nitric oxide (NO) in Ebola patients who died than in those who survived (4). High NO levels could have been produced by cytokine-induced overexpression of inducible NO synthase (iNOS) by mononuclear or other cells, or they could have led to the formation of peroxynitrite and other toxic molecules. The balance between iNOS and endothelial NOS (eNOS) is important because eNOS maintains endothelial barrier integrity (5, 6). Wiwanikit also notes that the addition of an NO donor can compromise the antihypertensive effect of ARB treatment (7), but this does not seem relevant to the effects of ARBs on endothelial barrier integrity.

Third, Wiwanikit notes that statin pretreatment failed to attenuate the reduction in forearm-mediated dilatation (FMD) caused by a short episode of ischemia/reperfusion (IR) (8). It is unclear how these changes in healthy subjects correlate with the broader aspects of IR-induced endothelial dysfunction seen in patients with inflammatory diseases such as acute myocardial infarction. In these patients, the anti-inflammatory effects of statins reduce periprocedural major cardiovascular events in patients undergoing percutaneous interventions (9, 10) and in those undergoing noncardiac surgery (11).

Fourth, Wiwanikit suggests that statin treatment of Ebola patients might cause autoimmune-mediated necrotizing myopathy (12). This condition has not been reported in large-scale clinical trials (13), and it occurs in only 2 cases per million years of treatment (14). Moreover, large randomized controlled trials have documented the safety of statin treatment in patients with acute critical illness (see, for example, reference 15). These reports provide reassurance on the safety of treating Ebola patients with atorvastatin and irbesartan.

Ebola scientists have been reluctant to consider treatments that target the host response (16). Instead, they favor targeting the virus with agents shown to be promising in nonhuman primate models of Ebola. In September 2014, the World Health Organization prioritized several of these antiviral agents and convalescent plasma for clinical trials in West Africa (17). One antiviral agent (favipiravir) was shown to reduce mortality in patients with low virus loads, but it failed to affect the 85% mortality in those with high virus loads (18). None of the other trials was successful, leading two observers to call the overall Ebola clinical trial experience a “thin scientific harvest” (19).

Atorvastatin and irbesartan have broad anti-inflammatory effects (20, 21), and combination treatment is more effective than treatment with either agent alone (22). Despite the opposition of Ebola scientists (16), we assumed that treatment with these drugs would maintain or restore endothelial barrier integrity (23), an assumption that has strong biological plausibility (24). Despite the reservations of Wiwanikit, the experience of physicians in Sierra Leone indicates that treating the host response in Ebola patients substantially improved survival (1, 25).

**FUNDING INFORMATION**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**REFERENCES**

1. Fedson DS, Jacobson JR, Rordam OM, Opal SM. 2015. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. mBio 6:e00076. [http://dx.doi.org/10.1128/mBio.00076-15](http://dx.doi.org/10.1128/mBio.00076-15).
2. Baskerville A, Fisher-Hoch SP, Neldh GH, Dowsett AB. 1985. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol 147:199–209. [http://dx.doi.org/10.1002/path.1711470308](http://dx.doi.org/10.1002/path.1711470308).
3. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. 1996. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 70:2208–2214.
4. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagener KD, Rollin PE. 2004. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78:10370–10377. [http://dx.doi.org/10.1128/JVI.78.19.10370–10377.2004](http://dx.doi.org/10.1128/JVI.78.19.10370–10377.2004).
5. Forsterrmann U, Sessa WC. 2012. Nitric oxide synthases: regulation and function. Eur Heart J 33:829–837. [http://dx.doi.org/10.1093/eurheartj/ech304](http://dx.doi.org/10.1093/eurheartj/ech304).
6. Di Lorenzo A, Lin MI, Murata T, Landskroner-Eiger S, Schleicher M, Kothiya M, Iwakiri Y, Yu J, Huang PL, Sessa WC. 2013. eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. J Cell Sci 126:5541–5552. [http://dx.doi.org/10.1242/jcs.115972](http://dx.doi.org/10.1242/jcs.115972).

**Published** 23 February 2016

**Citation** Fedson DS, Jacobson JR, Rordam OM, Opal SM. 2016. Reply to “Generic statins and angiotensin receptor blockers: are they really useful in Ebola?” mBio 7(1):e00094-16. [http://dx.doi.org/10.1128/mBio.00094-16](http://dx.doi.org/10.1128/mBio.00094-16).

**Copyright** © 2016 Fedson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
7. Yahiro E, Miura S, Suematsu Y, Matsuoy Y, Arinuma T, Kuwano T, Imaiuzumi S, Iwata A, Uehara Y, Sakai K. 2015. Addition of a nitric oxide donor to an angiotensin II type 1 receptor blocker may cancel its blood pressure-lowering effects. Int Heart J 56:566–600. http://dx.doi.org/10.1536/ihj.15-200.

8. Wouters CW, Wever KE, Bronckers I, Hopman MT, Smits P, Thijssen DH, Rongen GA. 2012. Short-term statin treatment does not prevent ischemia and reperfusion-induced endothelial dysfunction in humans. J Cardiovasc Pharmacol 59:22–28. http://dx.doi.org/10.1097/FJC.0b013e318232ba14.

9. Norris DM, Anderson JR. 2012. Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiovasc Rev 20:319–324. http://dx.doi.org/10.1097/CNR.0b013e31825db7ff.

10. Liang D, Zhang Q, Yang H, Zhang R, Yan W, Gao H, Wang J, Zhang X, Chen Y, Cao F. 2014. Anti-oxidative stress effect of loading-dose rosuvastatin prior to percutaneous coronary intervention in patients with acute coronary syndrome: a prospective randomized controlled clinical trial. Clin Drug Investig 34:773–781. http://dx.doi.org/10.1007/s40261-014-0231-0.

11. Berwanger O, Le Manach Y, Suzumura EA, Biccard B, Srinathan SK, Szczeklik W, Santo JA, Santucci E, Cavalcanti AB, Archbold RA, Devereux PJ, VISION Investigators. 2016. Association between preoperative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study. Eur Heart J 37:177–185. http://dx.doi.org/10.1093/eurheartj/ehv456.

12. Quinn C, Salameh J, Smith T, Souayah N. 2015. Necrotizing myopathies: an update. J Clin Neuromuscul Dis 16:370–377. http://dx.doi.org/10.1097/CND.0000000000000065.

13. Ganga HV, Slim HB, Thompson PD. 2014. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168:6–15. http://dx.doi.org/10.1016/j.ahj.2014.03.019.

14. Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Imaiuzumi S, Iwata A, Uehara Y, Sakai K. 2015. Addition of a nitric oxide donor to an angiotensin II type 1 receptor blocker may cancel its blood pressure-lowering effects. Int Heart J 56:566–600. http://dx.doi.org/10.1536/ihj.15-200.

15. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Tuwhit JD, Bernard GR, Stengrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholz C, Rock P, Douglas IS, deBoisblanc BP, Hough CL, Hite RD, Thompson BT. 2014. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 370:2191–2200. http://dx.doi.org/10.1056/NEJMoa1401520.

16. Enserink M. 2014. Infectious diseases. Debate erupts on “repurposed” drugs for Ebola. Science 345:718–719. http://dx.doi.org/10.1126/science.345.6198.718.

17. World Health Organization. 4–5 September 2014. WHO consultation on potential Ebola therapies and vaccines. Meeting summary. World Health Organization, Geneva, Switzerland. Accessed 15 November 2014. http://www.who.int/csr/resources/publications/ebola/ebola-therapies/en/. Accessed 15 November 2014.

18. Siissoko D, Anglaret X, Malvy D, Folkesson E, Abdoul M, Shepherd S, Danel C, Mentre F, Gunther S. 23–26 February 2015. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea, abst 103-ALB. Conf Retroviruses Opportunistic Infect 2015, Seattle, WA. http://www.croiconference.org/sessions/favipiravir-patients-ebola-virus-disease-early-results-jiki-trial-guinea. Accessed 15 July 2015.

19. Cohen J, Enserink M. 2016. As Ebola epidemic draws to a close, a thin scientific harvest. Science 351:12–13. http://dx.doi.org/10.1126/science.351.6268.12.

20. Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. 2014. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol 63:2491–2502. http://dx.doi.org/10.1016/j.jacc.2014.01.054.

21. Di Raimondo D, Tuttolomondo A, Buttà C, Miceli S, Licata G, Pinto A. 2012. Effects of ACE inhibitors and angiotensin receptor blockers on inflammation. Curr Pharmacol Des 18:4385–4413. http://dx.doi.org/10.2174/138161212802481282.

22. Lee HY, Sakuma I, Ihm SH, Goh CW, Koh KK. 2014. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 78:281–287. http://dx.doi.org/10.1253/circj.CJ-13-1494.

23. Fedson DS. 2015. A practical treatment for patients with Ebola virus disease. J Infect Dis 211:661–662. http://dx.doi.org/10.1093/infdis/jiu474.

24. Filewod NC, Lee WL. 2015. Is strengthening the endothelial barrier a therapeutic strategy for Ebola? Int J Infect Dis 36:78–79. http://dx.doi.org/10.1016/j.ijid.2015.05.016.

25. Fedson DS, Rordam OM. 2015. Treating Ebola patients: a “bottom up” approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 36:80–84. http://dx.doi.org/10.1016/j.ijid.2015.04.019.

26. Wiwanitkit V. 2016. Generic statins and angiotensin receptor blockers: are they really useful in Ebola? mBio 7(1):e02228-15. http://dx.doi.org/10.1128/mBio.02228-15.